Trexquant Investment LP Altimmune, Inc. Transaction History

Trexquant Investment LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$5.91 - $10.23 $207,517 - $359,205	35,113 New	35,113 $233,000
Q2 2022 Aug 11, 2022	SELL	$3.94 - $11.77 $391,119 - $1.17 Million	-99,269 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$5.9 - $9.45 $89,290 - $143,016	15,134 Added 17.99%	99,269 $605,000
Q4 2021 Feb 14, 2022	BUY	$8.69 - $12.48 $574,330 - $824,815	66,091 Added 366.28%	84,135 $771,000
Q3 2021 Nov 12, 2021	BUY	$8.43 - $16.81 $152,110 - $303,319	18,044 New	18,044 $204,000
Q2 2021 Aug 12, 2021	SELL	$9.85 - $16.46 $304,867 - $509,453	-30,951 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$12.71 - $24.31 $393,387 - $752,418	30,951 New	30,951 $437,000

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $426M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

Stay updated on Trexquant Investment LP with notifications on news.